史赛克签署收购ZuriMED的正式协议，以增强其肩部产品组合-动脉网

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

GlobeNewswire 等信源发布 2026-08-31 20:05



可切换为仅中文







Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

美国密歇根州波蒂奇，2026年8月31日（环球新闻社）--

Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.

史赛克已签署最终协议，收购ZuriMED公司。ZuriMED是FiberLocker系统的开发商，该技术已商业化，为肩袖增强提供了一种旨在提高生物力学强度的创新方法。

The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.

此次收购强化了史赛克的肩部产品组合，提升了其在整个护理连续体中为专科医生提供支持的能力。

The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.

FiberLocker 系统是一种软组织增强技术，旨在降低肩袖修复术中一种关键临床失败模式的发生率；肩袖修复是运动医学领域中增长最快的细分市场之一。

Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker

医疗技术全球领导者史赛克公司（纽约证券交易所代码：SYK）宣布，已签署最终协议，收购私营公司ZuriMED及其研发的FiberLocker。

System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.

系统。这项商业化技术为肩袖增强提供了一种新颖的方法，通过提高生物力学强度来解决肩袖修复中的一个关键临床失败模式。

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine and represents a significant opportunity within shoulder care.

肩袖增强术是运动医学中增长最快的领域之一，也为肩部护理带来了重要的发展机遇。

The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.

此次收购将增强史赛克在运动医学和关节置换领域支持肩关节专家的能力，并强化其在肩袖增强产品组合方面的实力。

“ZuriMED has developed a differentiated technology that addresses an important clinical need within shoulder care,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio. This acquisition reflects our continued commitment to advancing innovation and improving patient outcomes.”.

史赛克集团医疗外科与神经技术总裁安迪·皮尔斯表示：“ZuriMED开发了一种差异化技术，满足了肩部护理领域重要的临床需求。我们很高兴有机会将FiberLocker系统纳入史赛克的产品组合。此次收购体现了我们持续推进创新、改善患者预后的坚定承诺。”

This transaction is subject to customary closing conditions. Stryker and ZuriMED will continue to operate as separate entities and proceed with business as usual until the transaction closes.

本次交易须满足惯例交割条件。在交易完成之前，Stryker 和 ZuriMED 将继续作为独立实体运营，并照常开展业务。

About Stryker

关于史赛克

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually.

史赛克是全球医疗技术领域的领导者，我们与客户携手，致力于改善医疗保健。我们在医疗外科、神经技术和骨科领域提供创新的产品和服务，以提升患者疗效和医疗成果。我们与全球客户并肩合作，每年惠及超过1.5亿患者。

More information is available at .

更多信息可在 . 获取。

www.stryker.com

。

Contacts

联系人

For investor inquiries:

投资者咨询：

Nick Mead

尼克·米德

Vice President, Investor Relations